MCM
BIVV

Matarin Capital Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Matarin Capital Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,369
Closed -$443K – 314
2017
Q2 		$443K Buy
7,369
+1,100
+18% +$62.6K 0.04% 226
2017
Q1 		$341K Buy
+6,269
New +$309K 0.03% 245

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Matarin Capital Management's BIVV Position: Q3 2017 in Review

Matarin Capital Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q3 2017, closing a stake of 7,369 shares — an estimated $443K sold.

Matarin Capital Management first reported a position in BIVV in Q1 2017 and held it in 2 quarters. The position peaked at $443K in Q2 2017. 446 funds tracked by Wall St. Rank hold BIVV as of Q3 2017.

  • Matarin Capital Management reported no remaining Bioverativ Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Matarin Capital Management sold 7,369 Bioverativ Inc. Common Stock shares in Q3 2017, an estimated $443K.
  • Matarin Capital Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Matarin Capital Management's Bioverativ Inc. Common Stock position peaked at $443K in Q2 2017.
  • 446 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q3 2017.

Based on Matarin Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.